Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, a person close to the matter told Fierce Pharma. The layoffs are ...

In 2024’s fourth quarter, Moderna’s cost of sales came out to $739 million, including $193 million in inventory write-downs and production wind-down costs of $259 million. In that latter ...

Moderna secures a multi-year agreement to supply its COVID-19 vaccine to 17 European countries, including Norway and North Macedonia. Vaccine formats include prefilled syringes, reducing ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the ...

Moderna's stock roared higher on the back of news about potential AI mRNA vaccines. The company also secured a supply contract in Europe. Shares of Moderna are down 90%, and the company has a huge ...

Rice noodle dishes are some of the most popular at Asian restaurants—pad see ew, pad Thai, pho, and mei fun—but cooking them at home can be tricky if you’re not familiar with their quirks.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in Moderna today. 1. You can expect its revenue to fall further ...

Following four straight sessions of gains, Moderna (NASDAQ:MRNA) shares continued to trade higher in the premarket on Friday after the company received a tender to supply its COVID-19 vaccine in ...

The American pharmaceutical company Moderna is developing an mRNA-based vaccine candidate for norovirus, designated as mRNA-1403. This vaccine is designed to protect against multiple norovirus ...

A year earlier, Moderna earned $217 million, or 55 cents a share. The company's fourth-quarter sales slid 65% to $966 million, above analysts’ expectations.. Shares rose almost 3% Friday afternoon.

Sales at the once-high-flying biotech will likely continue to shrink for a while. But Moderna has a new cash cow in development, along with other potential winners. The U.S. government should ...